AMPK Activator for NDI

About NephroDi Therapeutics

NephroDI Therapeutics is a rare disease biotech targeting nephrogenic diabetes insipidus (NDI), a severe pediatric orphan condition causing extreme thirst and urine output. Its core asset is a novel, selective AMPK activator designed to concentrate urine without causing hypoglycemia, a key limitation of existing AMPK drugs. The company has secured a significant development partnership with Otsuka Pharmaceutical and The McQuade Center for Strategic R&D (MSRD), providing non-dilutive funding and expertise to advance its lead candidate. Led by a seasoned CEO with a strong translational track record and founded by leading renal researchers, NephroDI is positioned to address a high unmet need with no approved therapies.

Therapeutic Areas